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Abstract
Diagnosis of cancer at an early stage leads to improved survival. However, most current blood tests detect single
biomarkers that are of limited suitability for screening, and existing screening programmes look only for cancers of
one particular type. A new approach is needed. Recent developments suggest the possibility of blood-based
screening for multiple tumour types. It may be feasible to develop a high-sensitivity general screen for cancer
using multiple proteins and nucleic acids present in the blood of cancer patients, based on the biological
characteristics of cancer. Positive samples in the general screen would be submitted automatically for secondary
screening using tests to help define the likelihood of cancer and provide some indication of its type. Only those at
high risk would be referred for further clinical assessment to permit early treatment and mitigate potential
overdiagnosis. While the assays required for each step exist, they have not been used in this way. Recent
experience of screening for breast, cervical and ovarian cancers suggest that there is likely to be widespread
acceptance of such a strategy.
Introduction
Several successful screening programmes are already well
established, but these are currently applicable only to com-
mon cancers such as the faecal occult blood test [1] for
colorectal cancer, mammography for breast cancer [2]
and, of course, cervical cytology for cervical cancer and
dysplasia, which is becoming ever more sophisticated
[3,4]. Despite many attempts, blood tests have a less distin-
guished record. For instance, prostate-specific antigen
screening is widely used despite its well-publicised pro-
blems [5]. It remains controversial and generates large
numbers of papers every year (2, 032 were indexed in
PubMed through 2010 using the search terms ‘screening’,
‘prostate specific antigen’ and ‘cancer’). Many other
tumour markers have been described, usually in relatively
small studies, and few make it through to clinical use.
Cancer antigen 125 (CA 125) was first described as a mar-
ker of ovarian cancer in 1981 [6] and is still being evalu-
ated as a potential screening test [7,8].
Despite its history, blood-based screening for cancer
remains attractive, as it could provide inexpensive testing
t h a tw o u l da r g u a b l yb em o r ea c c e p t a b l et op a t i e n t sa n d
easily incorporated into an annual checkup, which might
include cholesterol and other assays of general health.
This idea was judged too risky to be funded when put
forward in 2005, but six years later, the recent review
along similar lines by Hanash et al.[ 9 ]h a ss h o w nh o w
fast the necessary underlying science is advancing. There
is no doubt that cancers have characteristics that could
be detected by performing blood-based screening tests
Figure 1. In 2000, Hanahan and Weinberg [10] published
their seminal paper describing the Hallmarks of Cancer,
and many authors since then have described changes in
blood related to these characteristics. Hanahan and
Weinberg pointed out that cancer cell growth is the
result of self-sufficiency in growth signals and insensitiv-
ity to antigrowth signals. Such signals are often mediated
by growth factors, which may rise above normal levels in
peripheral blood [11]. Growth has consequences: Even in
the early stages there may be detectable metabolic
changes [12,13], though these often lack specificity [14].
Cancer cells also upregulate mechanisms that allow them
to evade apoptosis, and some of these also cause the
release of cytokines into blood [15,16]. Many tumours
also have increased cell turnover: They grow because
they divide faster than they die, but there is still increased
cell death by apoptosis or necrosis. This overloads
the local clearance mechanisms for dead cells in tissues
and leads to the appearance of partly caspase-digested
Correspondence: ian.cree@porthosp.nhs.uk
Translational Oncology Research Centre, Queen Alexandra Hospital,
Southwick Hill, Portsmouth, PO6 3LY, UK
Cree BMC Cancer 2011, 11:499
http://www.biomedcentral.com/1471-2407/11/499
© 2011 Cree; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.proteins and DNA fragments in peripheral blood [17-19].
The amount of DNA present is increased and may con-
tain mutations or altered methylation [20-23]. More
recently, the presence of RNA, particularly in the form of
miRNA [24,25] and exosomes [25-27] derived from can-
cer cells in blood, has opened up new avenues of
research. Tumours require the ability to make new blood
vessels, and many therefore produce proangiogenic fac-
tors, which can be found in blood [28,29]. They also
increase the number of endothelial cell precursors in
blood [29]. Immunological abnormalities are common in
many cancer patients, with the appearance of autoantibo-
dies to p53 and other intracellular antigens [30]. Finally,
malignant cells invade and metastasise. While few meta-
static cells survive and grow, their presence can be
detected in blood by using sensitive assays [31].
Discussion
The question, therefore, is, Is it possible to use a general
screen that might select a set of individuals from the
general population who could then be screened further,
i n i t i a l l yb yu s i n gt h es a m eb l o o ds a m p l e ,t oc o n f i r m
whether they have cancer and give some guidance as to
type? While the objective of general population screen-
ing is to identify individuals with a high risk of cancer,
the aims of secondary and finally diagnostic screening
would be, respectively, to (1) confirm positivity and (2)
determine the type of cancer to assist in the choice of
further investigations to perform in a selected at-risk
group. The advantage of the two-stage method proposed
is that those tests showing greatest specificity often have
limited sensitivity. Circulating free DNA is a good exam-
ple of a test with considerable sensitivity [32,33], but
measurement of this alone in patients with inflammatory
or other conditions could lead to an unacceptably high
false-positive rate and might give little indication of the
site of the tumour [34,35]. Equally true is that studies of
gene mutations or autoantibodies may have greater spe-
cificity but lower sensitivity [21,30].
Preventive maintenance is routine for any complex
mechanical device and is increasingly acceptable to
healthy people. In most European countries, general
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Figure 1 Tumour biomarkers in blood reflect the major processes resulting in tumour formation by cancer cells and the host reaction.
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sure control, and blood tests are used to guide the use of
lipid-lowering drugs [36]. Highly successful screening
methods are used for specific cancers, as discussed above.
However, other common cancers for which no effective
screening methods exist include cancers of the lung, sto-
m a c h ,o e s o p h a g u s ,p a n c r e a s ,l i v e r ,h e a da n dn e c k ,a n d
kidney. Further, about 25% of cancer deaths occur as a
result of cancers outside the ‘top 10’ common cancer
types (Cancer Research UK: Cancer Mortality: UK Statis-
tics. Available at http://info.cancerresearchuk.org/cancer-
stats/mortality/). Although the economic implications
require careful study, it is possible that such screening
tests could be cost-neutral to health care providers, since
it is likely to be very much more expensive to treat a
small number of patients for advanced cancer than to
screen and treat a larger number of individuals with early
cancer or precancerous conditions. The benefit to
patients would be that a frequent, simple, low-risk and
relatively painless investigation could prevent serious or
life-threatening disease.
If the development of this strategy is successful, we will
see a general change from self-referral for cancer symp-
toms, when treatment is often difficult, costly and unsuc-
cessful, to regular screening using a simple blood test,
permitting the treatment of small, localised tumours.
New, less invasive radiological and treatment strategies
are required, but these are already being introduced, such
as laparoscopic surgery for colorectal carcinoma [37] and
endomucosal resection of oesophageal cancers [38].
Some of the patients undergoing screening are likely to
have anxieties related to the outcomes of their yearly
tests, but these are arguably balanced by the knowledge
that many cancers caught early are in most cases unlikely
to be fatal. The excellent take-up of existing screening
procedures (some quite unpleasant for patients) suggests
that this is not a major issue, though it is certainly a
research need and the introduction of screening proce-
dures requires careful evaluation [39].
The major risk to patients is overdiagnosis, which has
been highlighted by other screening programmes [40].
For quantitative blood tests, mitigation of this risk may
be feasible by setting test thresholds appropriately so that
only those at high risk are referred for further investiga-
tion, but this does require careful monitoring and quality
assurance is essential.
Many of the problems alluded to are common to most
translational research. Test development is the first stage
(Table 1). It is unlikely that any one analyte will provide
the answer, but several of them tested together or sequen-
tially in the same sample could provide the degree of accu-
racy needed. This would be particularly attractive if the
same or similar technologies were used for detection. The
recent use of human epididymis protein 4 and CA 125
detection for ovarian cancer (now approved by the US
Food and Drug Administration for monitoring disease) is
a case in point where the use of multiple analytes mea-
sured by ELISA was found to provide better information
than previous screening tests [41]. At present, there are
numerous published studies in these areas that could be
described as developmental (stage 1) or early clinical test-
ing (stage 2), but few of these (even those with strongly
positive results) go on to validation studies (stage 3),
which require larger series of well-documented patients.
Most stage 2 studies have too few patients to draw firm
conclusions. This has recently been noted with regard to
pharmacogenomic studies [42] and is by no means the
preserve of cancer, where the research community at least
has access to valuable information derived from large clin-
ical trials that can be used for cancer screening. Imple-
mentation studies that examine the impact and cost-
effectiveness of blood screens for cancer are very rare,
mainly because they are large, complex, time-consuming
and expensive to run.
Last, at each stage, the dissemination of results is
essential. A quick search of PubMed using the terms
‘early’, ‘detection’, ‘cancer’ and ‘validation’ produced 481
articles, 100 of which were classified as reviews and only
178 of which were available as free full-text articles.
BMC Cancer is, of course, a free full-text journal, and
our experience is that publication in this format aids in
the dissemination of results beyond the well-funded
libraries at major universities and hospitals.
Conclusion
General screens for cancer may be feasible but are unli-
kely to grow out of existing specialist screening pro-
grammes, which concentrate on particular cancer types.
Multiplex approaches are likely to be most effective and,
with appropriate translational support, could be practic-
able. There are a number of risks, mainly of overdiagno-
sis, which need careful management. Implementation
Table 1 Stages of translation from diagnostic to clinic for diagnostic devices
a
Stage Stage description
Stage 1 Development of test using clinical samples
Stage 2 Early clinical testing of efficacy (sensitivity, specificity, NPV, PPV, AUROC)
Stage 3 Validation (larger numbers, defined by confidence intervals on AUROC)
Stage 4 Implementation and impact (trials or modelling to answer effectiveness questions)
aAUROC: area under the receiver operating characteristic curve, NPV: negative predictive value, PPV, positive predictive value.
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Page 3 of 5depends on dissemination of research, and open access
journals have their role to play if this is to be become a
reality.
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